MAP2K3 and esophageal cancer: In esophageal cancer, Xie et al. [27] reported that Gossypetin inhibits the MKK3/6-p38 MAPK signaling pathway, hampering cell proliferation and motility and promoting apoptosis in different esophageal tumor lines (KYSE30, KYSE410, KYSE450, KYSE510), and patient-derived tumor tissue [27].